Emerging data revealed PI3K/AKT/mTOR signaling implicated in the progression of CRC and that components of the mTOR pathway were overexpressed in CRC.9 In recent studies, a new oral-specific AKT1/2/3 inhibitor, MK-2206, provided in vitro and in vivo antitumor activity as a single agent, as well as enhanced activity in combination with conventional chemotherapeutics.10–13 In addition, MK-2206 has been shown to be safe in humans, with early evidence of antitumor activity in clinical trials.14,15. This evidence concerns the gene AKT1 and colorectal carcinoma.